Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment

Chinese Journal of Oncology

Volumn 34, Issue 8, 2012, Pages 632-636

  Zhao, Fang Hui ^a   Chen, Jun Feng ^a   Gao, Xiao Hong ^a   Gao, Li Min ^a   Liu, Qi Gui ^a   Liu, Zhi Hua ^a   Xu, He ^a   Ma, Jun Fei ^a   Ma, Li ^a   Xu, Xiao Ling ^a   Hu, Shang Ying ^a   Ning, Yan ^a   Shi, Ju Fang ^a   Qiao, You Lin ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Cost benefit analysis; Costs and cost analysis; Mass screening; Uterine cervical neoplasms

Indexed keywords

LUGOL; VIRUS DNA;

ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; EARLY DIAGNOSIS; FEMALE; HEALTH ECONOMICS; HUMAN; PAPANICOLAOU TEST; QUALITY OF LIFE; RURAL AREA; STAINING; URBAN AREA; UTERINE CERVIX CANCER;

ACETIC ACID; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; COST-BENEFIT ANALYSIS; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IODIDES; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; RURAL POPULATION; URBAN POPULATION; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84866505888     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2012.08.017     Document Type: Article

References (16)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon: International Agency for Research on Cancer. 2010[2012-03-29]. http://globocan.iarc.fr.
2. Zhao FH, Lin MJ, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol, 2010, 11:1160-1171.
3. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer, 2006, 119:1095-1101.
4. Qiao YL, Sellons JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol, 2008, 9:929-936.
5. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol, 2001, 83:439-444.
6. de Kok IM, van Rosmalen J, Dillner J, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ, 2012, 344:e670.
7. van Rosmalen J, de Kok IM, van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG, 2012, 119:699-709.
8. Women's health in rural China. Lancet, 2009, 374:358.
9. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol, 2008, 9:425-434.
10. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr, 2003:14-19.
11. Levin CE, Sellors J, Shi JF, et al. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer, 2010, 127:1404-1411.
12. Shi JF, Canfell K, Lew JB, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer, 2011, 11:239.
13. Zhao FH, Lewkowitz AK, Chen F, et al. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst, 2012, 104:178-188.